{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-049281","form_type":"8-K","ticker":"ARWR","cik":"0000879407","company_name":"ARROWHEAD PHARMACEUTICALS, INC.","filed_at":"2024-11-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:11.205320+00:00","generated_at":"2026-05-29T18:26:14.150570+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Arrowhead reports FY2024 net loss $599.5M; inks Sarepta deal, files plozasiran NDA","bullets":["Net loss of $599.5M (-$5.00 diluted EPS) vs $205.3M loss (-$1.92) in FY2023.","Revenue fell to $3.55M from $240.7M, primarily due to lower collaboration revenue.","Signed licensing deal with Sarepta: $825M upfront ($500M cash, $325M equity), plus $250M over 5 years.","Closed $500M senior secured credit facility with Sixth Street; $400M funded at close.","Submitted NDA for plozasiran (FCS) and received Breakthrough Therapy designation from FDA."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-049281","json":"https://secwatch.observer/filing/0001628280-24-049281.json","markdown":"https://secwatch.observer/filing/0001628280-24-049281.md","text":"https://secwatch.observer/filing/0001628280-24-049281.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/879407/000162828024049281/0001628280-24-049281-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/879407/000162828024049281/arwr-20241126.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T18:26:14.150570+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}